Soon after it was first described that the vascular endothelial growth factor (VEGF) receptor blocker SU5416 (commonly known as "sugen"), in combination with chronic hypoxia, induced severe angioproliferative pulmonary arterial hypertension (PAH) in rats, critical voices pointed out the obvious paradox: why would an anti-angiogenic drug cause angioproliferation?More than a decade later, Norbert Voelkel and Jose Gomez-Arroyo, both from the Department of Biochemistry and Molecular Biology at Virginia Commonwealth University in Richmond, VA, attempt to address this question in a Translational Review of the cellular and molecular mechanisms underlying the development of PAH, with the intent of extending the concepts derived from the SU5416/ hypoxia rat model to generate a VEGF-centered hypothesis for the pathobiology of human forms of PAH.This review comprehensively walks the reader through the VEGF signaling pathways required to understand the postulated hypotheses of receptor tyrosine kinase remodeling, angiogenic rebound, and SU5416-like VEGF receptor endogenous inhibitors that complement the newly adopted concepts of quasi-malignant cell growth, apoptosis resistance and vascular inflammation.All of these concepts may collectively explain the development of PAH.